



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In the Application of: John E. Sims and Dirk E. Smith

Docket No.: 0317-US

Serial No.: 09/763,498

Group Art Unit: 1647

Filing Date: May 15, 2000

Examiner: F. Hamud

For: Human IL-1 epsilon DNA and Polypeptides

11/13
B.G.J.
12/2/02

RECEIVED

NOV 14 2002

RESPONSE TO OFFICE ACTION

Commissioner for Patents
Washington, D.C. 20231

TECH CENTER 1600/2900

Sir:

In response to an Office Action having a mailing date of July 2, 2002, Applicants request that the claims be amended as described, and reconsidered. A Petition for a One-Month Extension of Time is included herewith along with the fees necessary therefor.

In the claims:

Please amend claims 21 through 35, 38 and 39 to read as follows. A marked-up copy of the claims is appended hereto. In the marked-up copy, material to be deleted is marked with a strikethrough (~~strikethrough~~) and material to be inserted is underlined.

21. (amended) An isolated nucleic acid molecule selected from the group consisting of:

- (a) a DNA comprising a polynucleotide that encodes a polypeptide selected from the group consisting of SEQ ID NO:6, SEQ ID NO:8, and SEQ ID NO:13;
- (b) DNA comprising a polynucleotide that encodes a fragment of a polypeptide selected from the group consisting SEQ ID NO:8 and SEQ ID NO:13, wherein the fragment is active in IKB α or p38 MAP kinase phosphorylation or the fragment is active in cell surface expression of ICAM-1; and
- (c) DNA comprising a polynucleotide selected from the group consisting of SEQ ID NO:5, SEQ ID NO:7, and SEQ ID NO:12.

B'